Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval

News
Article

The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA

An image shows Nuance Audio hearing aid glasses, which pair directional microphones with open-ear speakers. Image courtesy of EssilorLuxottica

Nuance Audio pairs directional microphones with open-ear speakers. Image courtesy of EssilorLuxottica

EssilorLuxottica has received a CE Mark under the Medical Devices Regulation of the European Medicines Agency for its Nuance Audio Glasses, which integrate open-ear hearing aids into a pair of smart glasses. Concurrently, the device received The over-the-counter device received an ISO Quality Management System certification for Hearing Aids. The CE Mark was issued concurrently with medical device approval from the US Food and Drug Administration. The sweep of approvals will allow the glasses to launch in the US and Europe simultaneously.1

“Two years ago, we set out to create a first-of-its-kind product that would change the way people see and hear," Francesco Milleri, Chairman and CEO of EssilorLuxottica, said in a press release. "We didn’t just aim to combine two medical devices—we created an entirely new smart glasses form factor to support the two human senses we depend on the most. It is not only groundbreaking, but also incredibly accessible. We’re pleased now to turn our focus to getting this life-changing technology into the hands of people around the world who truly need it."

Nuance Audio Hearing Aid Software is the first Software as Medical Device (SaMD) to received FDA clearance in the US. The smart glasses combine stylish frames with an open-ear hearing aid, which reduces crowding around the ear that happens when using both a hearing aid and glasses. “After decades of adoption barriers ranging from comfort to visibility, consumers will finally be able to see clearly and hear clearly with a single product that is both beautiful and highly functional,” the press release reads.

Following the CE marking, Nuance Audio Glasses will be available in Italy in Q1 2025, then will expand to include France, Germany, UK, and additional unnamed European markets progressively over the first half of 2025. In the US, Nuance Audio Glasses will be available for over-the-counter purchase in Q1 2025 in the US.

According to the press release, EssilorLuxottica’s aim in creating Nuance Audio was to tackle hearing device disuse due to stigma, discomfort, cost, and limited accessibility. According to the World Health Organization’s 2021 World Report on Hearing, approximately 1.25 billion people worldwide experience mild to moderate hearing loss.2 With the introduction of Nuance Audio, EssilorLuxottica hopes to encourage more widespread adoption of hearing aids without sacrificing visual acuity.

References

1. EssilorLuxottica receives FDA clearance and EU certifications for Nuance Audio, making it available to consumers in the U.S. and Europe. EssilorLuxottica. Press release. Published February 3, 2025. Accessed February 3, 2025. https://www.essilorluxottica.com/en/newsroom/press-releases/fda-clearance-and-eu-certifications-for-nuance-audio/
2. World Health Organization, World Report on Hearing, 2021, p. 40.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Related Content
© 2025 MJH Life Sciences

All rights reserved.